5-year results from the CLL14 study of venetoc... - CLL Support
5-year results from the CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
You need to be a member of this community to see this post.
Read more about...
42 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Update on The CLARITY Study
phase II trial that combined ibrutinib with venetoclax in patients with relapsed or refractory CLL....
Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
survival (PFS) at 24 months, compared with patients who received obinutuzumab plus chlorambucil:...
Updated Results: Combined Ibrutinib and Venetoclax for 1st lineTreatment for CLL
remission.
A total of 12 (15%) pts have come off trial. Five pts came off trial during IBR...
Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL
of 1 year of treatment. All patients had uMRD in the peripheral blood, and 78% had MRD negativity in
AbbVie Pharm--positive phase 3 for CLL!
of follow-up with treatment of venetoclax plus obinutuzumab show that these patients can experience...
Good end to a bad year... My MRD Results are in!
Late breaking CLL abstract at ASH 2017 - VR vs BR
Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL
Untreated Aussies needing treatment - great clinical trial just for you
